New User:

Forgot your password?

Stock Market & Financial Investment News

News For QLTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 5, 2014
07:04 EDTQLTIQLT Inc. announces results from QLT091001 Phase 2a clinical trial
QLT Inc. announced results from its multi-center, Phase 2a clinical trial of repeated treatments of oral QLT091001 in adult subjects with early age-related macular degeneration, or AMD, and impaired dark adaptation and/or impaired low luminance vision. The Company previously announced positive results from its Phase 1b clinical trials for QLT091001 in subjects with the rare inherited retinal degenerative diseases, Leber Congenital Amaurosis, or LCA, and Retinitis Pigmentosa, or RP. In this Phase 2a trial, oral doses of QLT091001 dosed once per week for 3 consecutive weeks with one additional dose the day after the third dose, showed trends in improvement in dark adaptation rate and in glare recovery time relative to placebo. QLT091001 treatment had an acceptable safety profile and was well-tolerated. David Saperstein, MD, QLT's Chief Medical Advisor, stated, "Dark adaptation and glare recovery in elderly patients, especially in patients with AMD, are a growing problem in our aging population. The trend towards rapid improved dark adaptation and glare recovery times in this small placebo-controlled trial is encouraging. This study represents the first clinical trial with QLT091001 outside of rare orphan disease indications. These encouraging proof of concept results warrant further research aimed at refining the dosing, and endpoint evaluation to further establish the clinical significance of these findings."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use